EUVIMEDEUVIMED entdecken
Crossref

Design, Optimization, and Characterization of Tranexamic Acid Microemulsion for Topical Delivery

Anayatollah Salimi, Kiana Naderinia, Behzad Sharif Makhmalzadeh

Iranian journal of pharmaceutical sciences · 22.06.2026

DOI: 10.22037/ijps.v22i1.45865 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Iranian journal of pharmaceutical sciences, erschienen am 22.06.2026. Verfasst von Anayatollah Salimi und 2 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study focuses on the design, optimization, and evaluation of tranexamic acid (TXA) microemulsions (ME-TXA) for topical delivery to manage melasma. TXA is an antifibrinolytic agent that competitively inhibits plasminogen activation and acts as a non-competitive plasmin inhibitor, reducing melanin synthesis and inflammation in pigment cells. Beyond melasma, TXA has demonstrated potential for treating various skin disorders, including post-inflammatory hyperpigmentation, melanin-related pigmentation disorders [1], and chronic inflammatory conditions such as atopic dermatitis and rosacea [2]. Studies suggest that TXA can be beneficial in treating melasma [3]. The microemulsions were formulated using Labrafac PG/Transcutol P as the oil phase, Tween 80 and Span 80 as surfactants, and propylene glycol (PG) (10:1 ratio) as a co-surfactant These systems offer advantages such as improved drug solubility, enhanced skin penetration, controlled release, and increased formulation stability, making them ideal for topical delivery of TXA [4]. Physicochemical properties, including particle size, viscosity, zeta potential, and permeability, were systematically analyzed. Characterization of the formulations demonstrated particle sizes ranging from 15.08 to 34.75 nm, viscosities between 147.83 and 300.3 cps, and zeta potentials from -1.7 to -13.2 mV, ensuring stability and homogeneity. In vitro release studies indicated a cumulative drug release of up to 99.3% over 24 hours, following first-order release kinetics. The optimized formulation demonstrated enhanced TXA solubility, stability, and controlled drug release compared to aqueous solutions. Skin permeation studies revealed significantly enhanced drug permeation, with the optimized formulation achieving a steady-state flux (Jss) of 5.544 mg/cm²·h and a permeability coefficient (P) of 0.1108 cm/h. In addition, the apparent diffusion coefficient (Dapp) analysis demonstrated a reduced lag time (Tlag) compared to aqueous TXA.” These findings highlight the potential of ME-TXA as a biocompatible and efficient drug delivery system, offering improved solubility, stability, controlled release, and enhanced transdermal permeability for the effective management of melasma.

Schlagwörter

tranexamic acidmicroemulsionstopical drug deliverymelasmaskin pigmentationtransdermal permeationcontrolled drug releaseparticle sizezeta potentialin vitro release kinetics

Zitieren

APA

Salimi, A., Naderinia, K., & Makhmalzadeh, B. S. (2026). Design, Optimization, and Characterization of Tranexamic Acid Microemulsion for Topical Delivery. Iranian journal of pharmaceutical sciences. https://doi.org/10.22037/ijps.v22i1.45865

Vancouver

Salimi A, Naderinia K, Makhmalzadeh BS. Design, Optimization, and Characterization of Tranexamic Acid Microemulsion for Topical Delivery. Iranian journal of pharmaceutical sciences. 2026. doi:10.22037/ijps.v22i1.45865

BibTeX
@article{Salimi2026,
  author = {Salimi, Anayatollah and Naderinia, Kiana and Makhmalzadeh, Behzad Sharif},
  title = {Design, Optimization, and Characterization of Tranexamic Acid Microemulsion for Topical Delivery},
  journal = {Iranian journal of pharmaceutical sciences},
  year = {2026},
  doi = {10.22037/ijps.v22i1.45865}
}
Kostenlos starten →